• Who we are
  • Key topics
  • Publications
  • Newsroom
  • JOB OPPORTUNITIES
  • Contact us
Login Login
Medicines for Europe
  • Generic medicines
    • Home
    • Medicines for Europe
      • Generic medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Biosimilar medicines
    • Home
    • Medicines for Europe
      • Biosimilar medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • DEFINITION
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • External resources
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Value added medicines
    • Home
    • Who we are
      • Value added medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Environment of value added medicines in Europe
      • Definition
      • THERAPEUTIC AREAS
      • Q&A
    • What’s new
      • Environment of value added medicines in Europe
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • Value Added Medicines award 2019
      • QUOTES
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Contact us
  • Events

New report reveals need for pricing and reimbursement and procurement reforms to ensure patient access and healthcare sustainability

Brussels - 1 March 2021

Open

Related Posts

  • Commission study highlights need for procurement reform to… 21 December 2022 To improve access to medicines, we need European-wide legal guidance…
  • One- Pager: New pricing models for generic medicines 10 October 2022 How can we ensure a sustainable healthcare system while safeguarding…
  • New report assesses progress on biosimilar medicine policies… 29 March 2021 Biosimilar medicines are increasingly relevant to public health as emphasised by the…
  • Protecting health: Active generic and biosimilar policies… 3 March 2020 Equitable and sustainable access to medicines is a concern across…
Medicines for Europe
MEMBER OF
IGBA EMVO
  • Contact us
  • Privacy Policy
Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11
Powered by Big Smile Agency
Medicines For Europe
  • Who we are
  • Key topics
  • Publications
  • Newsroom
  • Contact us
  • SECTOR GROUPS
    • Generic medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Biosimilar medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Value added medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
  • Events
  • JOB OPPORTUNITIES
 Tweet
 Tweet
 Tweet
 LinkedIn